ES2894963T3 - Variantes de TNFSF15 y DcR3 asociadas con la enfermedad de Crohn - Google Patents
Variantes de TNFSF15 y DcR3 asociadas con la enfermedad de Crohn Download PDFInfo
- Publication number
- ES2894963T3 ES2894963T3 ES18201967T ES18201967T ES2894963T3 ES 2894963 T3 ES2894963 T3 ES 2894963T3 ES 18201967 T ES18201967 T ES 18201967T ES 18201967 T ES18201967 T ES 18201967T ES 2894963 T3 ES2894963 T3 ES 2894963T3
- Authority
- ES
- Spain
- Prior art keywords
- seq
- subject
- variants
- tnfsf15
- crohn
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102100024587 Tumor necrosis factor ligand superfamily member 15 Human genes 0.000 title claims abstract description 79
- 208000011231 Crohn disease Diseases 0.000 title claims abstract description 59
- 101000830596 Homo sapiens Tumor necrosis factor ligand superfamily member 15 Proteins 0.000 title claims abstract description 52
- 101000597785 Homo sapiens Tumor necrosis factor receptor superfamily member 6B Proteins 0.000 title claims description 35
- 102100035284 Tumor necrosis factor receptor superfamily member 6B Human genes 0.000 title claims description 33
- 230000002068 genetic effect Effects 0.000 claims abstract description 33
- 238000000034 method Methods 0.000 claims abstract description 27
- 238000003556 assay Methods 0.000 claims abstract description 13
- 238000003205 genotyping method Methods 0.000 claims abstract description 12
- 108090000138 Tumor necrosis factor ligand superfamily member 15 Proteins 0.000 claims description 30
- 230000006698 induction Effects 0.000 claims description 3
- 206010016654 Fibrosis Diseases 0.000 description 16
- 230000004761 fibrosis Effects 0.000 description 16
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 9
- 206010061218 Inflammation Diseases 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 230000000968 intestinal effect Effects 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 101100033037 Mus musculus Rbbp6 gene Proteins 0.000 description 5
- 102000054766 genetic haplotypes Human genes 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 206010009887 colitis Diseases 0.000 description 4
- 239000012636 effector Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 206010028116 Mucosal inflammation Diseases 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000000513 principal component analysis Methods 0.000 description 3
- 102210021311 rs6478108 Human genes 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 108700028369 Alleles Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 206010072877 Intestinal fibrosis Diseases 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 102000054767 gene variant Human genes 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011477 surgical intervention Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000009058 Death Domain Receptors Human genes 0.000 description 1
- 108010049207 Death Domain Receptors Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 230000033289 adaptive immune response Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 208000009326 ileitis Diseases 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000012482 interaction analysis Methods 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000007477 logistic regression Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108700015048 receptor decoy activity proteins Proteins 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 102210011440 rs6478109 Human genes 0.000 description 1
- 102210013267 rs7848647 Human genes 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361824932P | 2013-05-17 | 2013-05-17 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| ES2894963T3 true ES2894963T3 (es) | 2022-02-16 |
| ES2894963T8 ES2894963T8 (es) | 2022-02-24 |
Family
ID=51899024
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES18201967T Active ES2894963T3 (es) | 2013-05-17 | 2014-05-16 | Variantes de TNFSF15 y DcR3 asociadas con la enfermedad de Crohn |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US20160090629A1 (cg-RX-API-DMAC7.html) |
| EP (3) | EP3498867B1 (cg-RX-API-DMAC7.html) |
| JP (5) | JP6482533B2 (cg-RX-API-DMAC7.html) |
| KR (4) | KR20230093538A (cg-RX-API-DMAC7.html) |
| CN (1) | CN105358713B (cg-RX-API-DMAC7.html) |
| ES (1) | ES2894963T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014186750A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110229471A1 (en) | 2008-11-26 | 2011-09-22 | Cedars-Sinai Medical Center | Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease |
| JP2014531210A (ja) | 2011-09-30 | 2014-11-27 | テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド | ＴＬ１ａに対する抗体およびその使用 |
| WO2014160883A1 (en) | 2013-03-27 | 2014-10-02 | Cedars-Sinai Medical Center | Treating fibrosis and inflammation by inhibiting tl1a |
| EP3498867B1 (en) | 2013-05-17 | 2021-09-29 | Cedars-Sinai Medical Center | Variants of tnfsf15 and dcr3 associated with crohn's disease |
| US10316083B2 (en) | 2013-07-19 | 2019-06-11 | Cedars-Sinai Medical Center | Signature of TL1A (TNFSF15) signaling pathway |
| EP3337465B1 (en) | 2015-08-21 | 2021-11-24 | The Children's Hospital of Philadelphia | Compositions and methods for use in combination for the treatment and diagnosis of autoimmune diseases |
| TWI703158B (zh) | 2015-09-18 | 2020-09-01 | 美商希佛隆公司 | 特異性結合tl1a之抗體 |
| KR20240095481A (ko) | 2016-03-17 | 2024-06-25 | 세다르스-신나이 메디칼 센터 | Rnaset2를 통한 염증성 장 질환의 진단 방법 |
| EP3458466B1 (en) * | 2016-05-20 | 2024-08-07 | Cedars-Sinai Medical Center | Diagnosis of inflammatory bowel disease based on genes |
| EP3846851A4 (en) * | 2018-09-07 | 2022-09-21 | The Children's Hospital Of Philadelphia | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING DISORDERS OF THE LYMPHATIC SYSTEM |
| KR20220088529A (ko) | 2019-05-14 | 2022-06-27 | 프로메테우스 바이오사이언시즈, 인크. | Tl1a 환자 선택 방법, 시스템 및 장치 |
| BR112022004590A2 (pt) * | 2019-09-13 | 2022-06-14 | Kyowa Kirin Co Ltd | Variante dcr3 |
| PH12023500011A1 (en) * | 2020-11-13 | 2024-03-11 | Cedars Sinai Medical Center | Methods, systems, and kits for treatment of inflammatory diseases targeting tl1a |
| WO2025038473A1 (en) | 2023-08-11 | 2025-02-20 | Paragon Therapeutics, Inc. | Tl1a binding antibodies and methods of use |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US20090186034A1 (en) * | 2006-12-19 | 2009-07-23 | Genetech, Inc. | Gene expression markers for inflammatory bowel disease |
| US20100190162A1 (en) | 2007-02-26 | 2010-07-29 | Cedars-Sinai Medical Center | Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease |
| WO2009052512A2 (en) | 2007-10-19 | 2009-04-23 | Cedars-Sinai Medical Center | Methods of using genetic variants to diagnose and predict inflammatory bowel disease |
| SI2257643T1 (sl) | 2008-02-19 | 2018-12-31 | The Children's Hospital Of Philadelphia | Identifikacija predelov vnetne črevesne bolezni z začetkom v otroštvu in metode za njeno uporabo za diagnozo in zdravljenje te bolezni |
| WO2010118210A1 (en) * | 2009-04-08 | 2010-10-14 | Cedars-Sinai Medical Center | Methods of predicting complication and surgery in crohn's disease |
| AU2010236568B2 (en) * | 2009-04-14 | 2015-08-27 | Société des Produits Nestlé S.A. | Inflammatory bowel disease prognostics |
| EP2630495B1 (en) | 2010-10-18 | 2017-02-08 | Nestec S.A. | Methods for determining anti-drug antibody isotypes |
| DK2676137T3 (en) | 2011-02-17 | 2015-01-19 | Nestec Sa | TESTS TO DETECT AUTO ANTIBODIES FOR ANTI-TNF PHARMACEUTICALS |
| WO2012161856A1 (en) * | 2011-05-20 | 2012-11-29 | Government Of The United States, As Represented By The Secretary, Department Of Health And Human Services | Blockade of tl1a-dr3 interactions to ameliorate t cell mediated disease pathology and antibodies thereof |
| CA2841416A1 (en) | 2011-06-15 | 2012-12-20 | Glaxosmithkline Intellectual Property (No.2) Limited | Method of selecting therapeutic indications |
| EP2565277A1 (en) | 2011-09-05 | 2013-03-06 | Progenika Biopharma, S.A. | Method for predicting radiographic severity in ankylosing spondylitis |
| JP2015502740A (ja) | 2011-10-21 | 2015-01-29 | ネステク ソシエテ アノニム | 炎症性腸疾患の診断を改善するための方法 |
| EP3498867B1 (en) | 2013-05-17 | 2021-09-29 | Cedars-Sinai Medical Center | Variants of tnfsf15 and dcr3 associated with crohn's disease |
| CR20180365A (es) | 2015-12-16 | 2018-09-28 | Amgen Inc | PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS |
| KR20240095481A (ko) | 2016-03-17 | 2024-06-25 | 세다르스-신나이 메디칼 센터 | Rnaset2를 통한 염증성 장 질환의 진단 방법 |
-
2014
- 2014-05-16 EP EP18201967.9A patent/EP3498867B1/en active Active
- 2014-05-16 WO PCT/US2014/038468 patent/WO2014186750A2/en not_active Ceased
- 2014-05-16 KR KR1020237020524A patent/KR20230093538A/ko not_active Ceased
- 2014-05-16 EP EP21193676.0A patent/EP3988673A3/en active Pending
- 2014-05-16 CN CN201480038133.6A patent/CN105358713B/zh active Active
- 2014-05-16 US US14/890,712 patent/US20160090629A1/en not_active Abandoned
- 2014-05-16 KR KR1020217026836A patent/KR20210107176A/ko not_active Ceased
- 2014-05-16 EP EP14797214.5A patent/EP2997165A4/en not_active Withdrawn
- 2014-05-16 ES ES18201967T patent/ES2894963T3/es active Active
- 2014-05-16 JP JP2016514143A patent/JP6482533B2/ja active Active
- 2014-05-16 KR KR1020157034355A patent/KR102295125B1/ko active Active
- 2014-05-16 KR KR1020257028341A patent/KR20250130857A/ko active Pending
-
2018
- 2018-04-05 US US15/946,632 patent/US20180230543A1/en not_active Abandoned
- 2018-06-29 JP JP2018124311A patent/JP2018148931A/ja not_active Withdrawn
-
2020
- 2020-06-03 JP JP2020096798A patent/JP2020127437A/ja not_active Withdrawn
-
2021
- 2021-08-02 US US17/392,098 patent/US12281359B2/en active Active
-
2022
- 2022-06-09 JP JP2022093628A patent/JP2022111329A/ja not_active Withdrawn
-
2024
- 2024-12-06 JP JP2024213907A patent/JP2025023316A/ja active Pending
-
2025
- 2025-03-19 US US19/084,586 patent/US20250243548A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014186750A3 (en) | 2015-01-08 |
| US20180230543A1 (en) | 2018-08-16 |
| EP2997165A4 (en) | 2017-03-08 |
| EP3988673A2 (en) | 2022-04-27 |
| KR20160009582A (ko) | 2016-01-26 |
| JP2022111329A (ja) | 2022-07-29 |
| US20250243548A1 (en) | 2025-07-31 |
| JP6482533B2 (ja) | 2019-03-13 |
| EP3498867B1 (en) | 2021-09-29 |
| KR20230093538A (ko) | 2023-06-27 |
| KR20210107176A (ko) | 2021-08-31 |
| WO2014186750A2 (en) | 2014-11-20 |
| EP3498867A1 (en) | 2019-06-19 |
| US20160090629A1 (en) | 2016-03-31 |
| JP2016526875A (ja) | 2016-09-08 |
| JP2018148931A (ja) | 2018-09-27 |
| ES2894963T8 (es) | 2022-02-24 |
| US12281359B2 (en) | 2025-04-22 |
| JP2025023316A (ja) | 2025-02-14 |
| EP3988673A3 (en) | 2022-08-03 |
| KR102295125B1 (ko) | 2021-08-31 |
| KR20250130857A (ko) | 2025-09-02 |
| JP2020127437A (ja) | 2020-08-27 |
| US20210371931A1 (en) | 2021-12-02 |
| EP2997165A2 (en) | 2016-03-23 |
| CN105358713A (zh) | 2016-02-24 |
| CN105358713B (zh) | 2020-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2894963T3 (es) | Variantes de TNFSF15 y DcR3 asociadas con la enfermedad de Crohn | |
| Werbrouck et al. | Acute normal tissue reactions in head-and-neck cancer patients treated with IMRT: influence of dose and association with genetic polymorphisms in DNA DSB repair genes | |
| US20160096885A1 (en) | Distinct effects of ifn-gamma and il-17 on tl1a modulated inflammation and fibrosis | |
| Mehrotra et al. | Genetic and functional evaluation of the role of DLL1 in susceptibility to visceral leishmaniasis in India | |
| Baatjes et al. | CYP19A1 rs10046 pharmacogenetics in postmenopausal breast cancer patients treated with aromatase inhibitors: one-year follow-up | |
| Szczepańska et al. | Involvement of vascular endothelial growth factor− 460 C/T,+ 405 G/C and+ 936 C/T polymorphisms in the development of endometriosis | |
| Teixeira et al. | SH3BP2-encoding exons involved in cherubism are not associated with central giant cell granuloma | |
| HK40072596A (en) | Variants of tnfsf15 and dcr3 associated with crohn's disease | |
| CN102787163B (zh) | 检测OTOF基因c.1671_1673delG突变的试剂盒 | |
| Kacerovska et al. | Carney complex: a clinicopathologic and molecular biological study of a sporadic case, including extracutaneous and cutaneous lesions and a novel mutation of the PRKAR1A gene | |
| CN106244727A (zh) | 一种hpv‑16与宿主遗传因素的联合效应的测试方法 | |
| Guan et al. | Risk of gastric ulcer contributed by genetic polymorphisms of PSCA: A case-control study based on Chinese Han population | |
| Hassan et al. | Genetic polymorphism of interleukin-4 gene in inflammatory bowel disease of Iraqi patients | |
| Francis et al. | Hypoxia responsiveness linked variant in EGLN1 gene is enriched in oral cancer patients | |
| Sapaev et al. | FORECASTING AND PREVENTION OF SPIKE FORMATION IN ACUTE INTESTINAL OBSTRUCTION | |
| Tezerjani et al. | Transforming growth factor Beta leucine10 proline variation and breast cancer risk in Iranian women | |
| Костенко et al. | GENETIC COMPONENT IN THE PREVALENCE OF DENTOFACIAL ANOMALIES IN CHILDREN | |
| Omelchenko et al. | POLYMORPHISMS IN THE GENES OF VASCULAR ENDOTHELIAL GROWTH FACTOR ARE ASSOCIATED WITH THE EARLIER ONSET OF RHEUMATOID ARTHRITIS | |
| CN102732615A (zh) | 检测OTOF基因c.2382_2383delC突变的试剂盒 | |
| Lucky et al. | (VDR) Gene Polymorphisms–Rapid and noninvasive oral detection Method | |
| Izquierdo et al. | 813 MOLECULAR CHARACTERIZATION OF UPPER URINARY TRACT TUMOURS | |
| Ruchusatsawat | Association of the interleukin-10 distal promoter (-2763A/C) polymorphism with late-onset psoriasis | |
| Cornu et al. | 814 IMPORTANCE OF ALLELIC INSTABILITY OF URINARY MICROSATELLITES MARKERS FOR CONSERVATIVE MANAGEMENT OF UPPER URINARY TRACT UROTHELIAL CELL CARCINOMA | |
| Rouprêt et al. | 812 GENETIC VARIABILITY WITHIN 8Q24 CONFERS ENHANCED RISK OF UROTHELIAL CELL CARCINOMA OF THE UPPER URINARY TRACT |